ICUI Stock Analysis: Buy, Sell, or Hold?
ICUI - ICU Medical Inc
$125.38
1.19 (0.96%)
▲
5d:
-3.5%
30d:
-16.74%
90d:
-15.21%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When ICUI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ICUI trading at deep discount. Market pricing in -7.7% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ICUI trading at deep discount. Market pricing in -7.7% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$241.59
Based on 8.8% avg growth
INTRINSIC VALUE TODAY
$150.01
16.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ICUI is currently trading at $125.38, which is considered oversold relative to its 30-day fair value range of $125.57 to $146.68. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.6) compared to its historical average (17.3). Remarkably, the market is currently pricing in an annual earnings decline of 7.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ICUI is showing sideways momentum. The price is currently testing key support at $123.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $182.67 (+45.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ICUI is showing sideways momentum. The price is currently testing key support at $123.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $182.67 (+45.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$125.57 -
$146.68
Company Quality Score
59/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.7% below Wall St target ($182.67)
Fair Price Analysis
30-Day Fair Range
$125.57 -
$146.68
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$8.43
(6.7%)
Support & Resistance Levels
Support Level
$123.20
Resistance Level
$132.84
Current Trend
Sideways
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.62
Wall Street Target
$182.67
(+45.7%)
Revenue Growth (YoY)
-14.1%
Earnings Growth (YoY)
-23.8%
Valuation Discount vs History
-7.7% cheaper
PE vs Historical
13.6 vs 17.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.7%
(market-implied from PE analysis)
1-Year Target
$115.73
(-8%)
2-Year Target
$106.81
(-15%)
3-Year Target
$98.59
(-21%)
3-Yr Target (if PE normalizes)
(PE: 14→17)
$125.19
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 13.5%)
$300.39
(+140%)
Base:
(SPY PE: 13.6, Growth: 13.5%)
$183.11
(+46%)
Bear:
(PE: 11.6, Growth: 13.5%)
$155.64
(+24%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Forward PE: 15.31 | Forward EPS (Implied): $8.48
Bull Case
$156.89
(+21%)
Analyst growth 15.0%, PE expands to 16.1
Base Case
$129.93
(0%)
Market implied 0.0%, PE stable at 15.3
Bear Case
$99.40
(-24%)
Severe decline -15.0%, PE contracts to 13.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.6 to 17.3
Stabilization Target:
$159.21
(+27.0%)
PE Expansion Potential:
+27.0%
Share & Embed Analysis
Last updated: March 31, 2026 6:12 AM ET
Data refreshes hourly during market hours. Next update: 7:12 AM
Data refreshes hourly during market hours. Next update: 7:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ICUI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Elisha W Finney
SELL
1285 shares
2025-11-11
Virginia Ruth Sanzone
SELL
930 shares
2025-11-11
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$607 | 55 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$94 | 55 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$186 | 57 HOLD |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$318 | 63 BUY |
|
AVTR
Avantor Inc |
HOLD
21 analysts |
$11 | 61 BUY |
